行情

MRTX

MRTX

Mirati
NASDAQ

实时行情|Nasdaq Last Sale

92.67
-0.77
-0.82%
交易中 12:06 09/23 EDT
开盘
93.00
昨收
93.44
最高
94.35
最低
92.58
成交量
12.37万
成交额
--
52周最高
111.99
52周最低
28.50
市值
36.42亿
市盈率(TTM)
-22.3183
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MRTX 新闻

  • 美国国务卿蓬佩奥谴责伊朗袭击沙特油田
  • 央视.09/14 22:10
  • 在美国腐败调查的阴影下 UAW和通用汽车接近合同期限
  • 新浪美股.09/14 21:54
  • 马斯克强调物流速度:亚马逊要像特斯拉一样早破产了
  • 新浪美股.09/14 20:38
  • 日韩交锋舞台转向WTO 日媒:对立或长期化
  • 参考消息.09/14 16:30

更多

所属板块

生物技术和医学研究
-0.35%
制药与医学研究
-0.19%

热门股票

名称
价格
涨跌幅

MRTX 简况

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).
展开

Webull提供Mirati Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。